Quidel Acquires Diagnostic Hybrids for US$130 Million

By LabMedica International staff writers
Posted on 15 Jan 2010

Quidel Corporation (San Diego, CA, USA) signed a definitive agreement to acquire the privately owned company Diagnostic Hybrids, Inc. (Athens, OH, USA) for approximately US$130 million in cash.

Quidel provides a variety of rapid point-of-care diagnostic tests marketed under the brand name of QuickVue. Diagnostic Hybrids manufactures and commercializes direct fluorescent in vitro diagnostic assays used in hospital and reference laboratories for a number of diseases.

Diagnostic Hybrids leverages its antibody development and cell culture expertise to develop new products that address significant market opportunities. The company's direct sales force serves over 700 North American customers, and its products are sold via distributors outside the United States.

"Diagnostic Hybrids will broaden Quidel's current portfolio into complementary nonseasonal infectious and autoimmune diseases and help diversify our revenue base. Moreover, Diagnostic Hybrids has a solid track record of generating strong and profitable sales growth," said Douglas Bryant, president and CEO of Quidel.

David Scholl, Ph.D., president and CEO of Diagnostic Hybrids Diagnostic added, "Our combined organization will have greater channel strength and together we will provide our customers a full service offering of best-in-class diagnostic products."

Quidel's portfolio of products currently includes tests that aid in the diagnosis of disease or condition states, including those caused by Chlamydia, fecal occult blood (FOB), respiratory viruses, herpes virus, other viruses; Helicobacter pylori, Streptococcus A; and pregnancy and thyroid disease tests. Quidel's products are sold to healthcare professionals on a worldwide basis.

Related Links:
Quidel Corporation
Diagnostic Hybrids

Visit expo >

Gold Member

Flocked Fiber Swabs

Puritan® Patented HydraFlock®

Online QC Software
Acusera 24•7

Prefilled Tubes

Prefilled 5.0ml Tubes

All-in-One Molecular System

AIO M160

Latest Industry News

Channels

Clinical Chemistry

view channel

Saliva-Based Test Detects Biochemical Signs of Sleep Loss

Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more

Image: Representational Models of Regional Aβ and Tau Deposition Across Plasma Stages (Salvadó G, Horie K, Barthélemy NR, et al. JAMA Neurology. May 26, 2026. doi:10.1001/jamaneurol.2026.1405)

Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease

Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more

Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia

Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more

Image: New urine test provides a simple way to screen for autism in children (Photo courtesy of Andy DeLisle/ASU Knowledge Enterprise)

Urine-Based Test Shows Promise for Autism Screening in Children

Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more

Molecular Diagnostics

view channel

New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance

Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more

Image: Graphical abstract (Pandya T, Zagorulya M, Leung MM, et al. Plasma signals of lung tumor promotion for molecular cancer prevention. Cell. 2026. doi:10.1016/j.cell.2026.05.005)

Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead

Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more

Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer

Adjuvant therapy decisions after curative surgery for colon cancer remain difficult, as conventional clinicopathologic factors often fail to capture residual disease risk. Liquid biopsy approaches that... Read more

Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers

A subset of cancers rely on alternative lengthening of telomeres, a pathway associated with genomic instability and difficult-to-treat disease. These tumors span multiple cancer types and account for about... Read more

Hematology

view channel

Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows

Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more

Image: Direct and indirect antitumoral effects of eosinophil (Marie Gilon et al., Journal of Experimental & Clinical Cancer Research (2026). DOI: 10.1186/s13046-026-03688-5)

Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity

Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more

Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children

Iron deficiency in school-age children can affect brain development, learning, growth, and physical performance, yet early deficiency may be missed when screening focuses mainly on anemia.... Read more

Image: Graphical abstract (Waclawiczek A, Leppä AM, Renders S, et al. Cell Stem Cell, 2026. doi:10.1016/j.stem.2026.04.012)

Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more

Immunology

view channel

Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection

Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more

Study Points to Autoimmune Pathway Behind Long COVID Symptoms

Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more

Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read more

Microbiology

view channel

New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs

Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more

Automated Blood Culture System Speeds Detection of Bloodstream Infections

Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read more

Image: Graphical Abstract (Microbiome Research Reports: DOI:10.20517/mrr.2025.96)

Gut Microbiome Signatures Help Identify Risk of IBD Progression

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more

FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets

Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read more

Pathology

view channel

3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer

Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more

Image: RMA reporter (magenta) expressed in response to neuronal activity marker (cyan) in the hippocampus (Image courtesy of Sho Watanabe/Rice University)

Blood-Based Method Tracks Gene Activity in the Living Brain

Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more

FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors

Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read more

AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes

Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more

Technology

view channel

AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines

Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more

Agentic AI Platform Supports Genomic Decision-Making in Oncology

Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more

Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps

Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more

Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance

Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read more